175 related articles for article (PubMed ID: 15795923)
1. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
[TBL] [Abstract][Full Text] [Related]
3. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.
Ide M; Kawachi Y; Izumi Y; Kasagi K; Ogino T
Eur J Haematol; 2006 Feb; 76(2):119-23. PubMed ID: 16405432
[TBL] [Abstract][Full Text] [Related]
4. A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.
Kantarci FE; Eren R; Gündoğan C; Huq GE; Doğu MH; Suyanı E
J Infect Chemother; 2016 Jul; 22(7):483-5. PubMed ID: 26948831
[TBL] [Abstract][Full Text] [Related]
5. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).
Ibrahim K; Maghfoor I; Elghazaly A; Bakshi N; Mohamed SY; Aljurf M
Hematol Oncol Stem Cell Ther; 2011; 4(2):100-2. PubMed ID: 21727772
[TBL] [Abstract][Full Text] [Related]
7. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands.
Seliem RM; Griffith RC; Harris NL; Beheshti J; Schiffman FJ; Longtine J; Kutok J; Ferry JA
Am J Surg Pathol; 2007 Sep; 31(9):1439-45. PubMed ID: 17721201
[TBL] [Abstract][Full Text] [Related]
8. Mixed variant multicentric Castleman disease treated with rituximab: case report.
Mian H; Leber B
J Pediatr Hematol Oncol; 2010 Nov; 32(8):622. PubMed ID: 20921905
[No Abstract] [Full Text] [Related]
9. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
Neuville S; Agbalika F; Rabian C; Brière J; Molina JM
Am J Hematol; 2005 Aug; 79(4):337-9. PubMed ID: 16044438
[TBL] [Abstract][Full Text] [Related]
10. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.
Casquero A; Barroso A; Fernández Guerrero ML; Górgolas M
Ann Hematol; 2006 Mar; 85(3):185-7. PubMed ID: 16341862
[TBL] [Abstract][Full Text] [Related]
11. Multicentric Castleman's disease & HIV infection.
Cotter A; Lambert J; O'Gorman P
Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
[TBL] [Abstract][Full Text] [Related]
12. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.
Galeotti C; Tran TA; Franchi-Abella S; Fabre M; Pariente D; Koné-Paut I
J Pediatr Hematol Oncol; 2008 Dec; 30(12):920-4. PubMed ID: 19131781
[TBL] [Abstract][Full Text] [Related]
13. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
14. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
15. What Is the best treatment for HIV-associated multicentric Castleman disease?
Bower M; Dalla Pria A
Clin Adv Hematol Oncol; 2012 Mar; 10(3):207-9. PubMed ID: 22402432
[No Abstract] [Full Text] [Related]
16. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy.
Koenig G; Stevens TM; Peker D
Histopathology; 2015 Dec; 67(6):930-2. PubMed ID: 25900626
[No Abstract] [Full Text] [Related]
17. A case of multicentric Castleman's disease in HIV infection with the rare complication of acquired angioedema.
Fernando I; Scott G
Int J STD AIDS; 2014 Jun; 25(7):523-5. PubMed ID: 24352125
[TBL] [Abstract][Full Text] [Related]
18. Human herpesvirus 8-related Castleman disease in the absence of HIV infection.
Dossier A; Meignin V; Fieschi C; Boutboul D; Oksenhendler E; Galicier L
Clin Infect Dis; 2013 Mar; 56(6):833-42. PubMed ID: 23223599
[TBL] [Abstract][Full Text] [Related]
19. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
Műzes G; Sipos F; Csomor J; Sréter L
APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
[TBL] [Abstract][Full Text] [Related]
20. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease.
Estephan FF; Elghetany MT; Berry M; Jones DV
Cancer Invest; 2005; 23(2):191. PubMed ID: 15813512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
